首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1686249篇
  免费   126404篇
  国内免费   3757篇
耳鼻咽喉   21725篇
儿科学   55557篇
妇产科学   46140篇
基础医学   240459篇
口腔科学   48695篇
临床医学   150445篇
内科学   331450篇
皮肤病学   38629篇
神经病学   130707篇
特种医学   63806篇
外国民族医学   242篇
外科学   256765篇
综合类   38829篇
现状与发展   4篇
一般理论   531篇
预防医学   123600篇
眼科学   40052篇
药学   123419篇
  7篇
中国医学   4435篇
肿瘤学   100913篇
  2021年   12345篇
  2019年   13519篇
  2018年   19949篇
  2017年   15212篇
  2016年   16611篇
  2015年   18957篇
  2014年   26212篇
  2013年   37940篇
  2012年   52724篇
  2011年   55415篇
  2010年   32768篇
  2009年   30691篇
  2008年   51514篇
  2007年   54793篇
  2006年   55252篇
  2005年   52535篇
  2004年   50737篇
  2003年   48147篇
  2002年   46366篇
  2001年   91782篇
  2000年   93605篇
  1999年   76959篇
  1998年   19717篇
  1997年   17200篇
  1996年   16418篇
  1995年   16636篇
  1994年   15228篇
  1993年   14000篇
  1992年   57307篇
  1991年   55258篇
  1990年   52945篇
  1989年   50724篇
  1988年   46108篇
  1987年   44920篇
  1986年   42194篇
  1985年   39978篇
  1984年   29311篇
  1983年   24844篇
  1982年   13842篇
  1979年   25467篇
  1978年   17528篇
  1977年   14849篇
  1976年   13829篇
  1975年   14513篇
  1974年   17601篇
  1973年   16907篇
  1972年   15664篇
  1971年   14433篇
  1970年   13415篇
  1969年   12504篇
排序方式: 共有10000条查询结果,搜索用时 594 毫秒
91.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
92.
93.
94.
95.
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris.  相似文献   
96.
97.
98.
Investigative studies of white matter (WM) brain structures using diffusion MRI (dMRI) tractography frequently require manual WM bundle segmentation, often called “virtual dissection.” Human errors and personal decisions make these manual segmentations hard to reproduce, which have not yet been quantified by the dMRI community. It is our opinion that if the field of dMRI tractography wants to be taken seriously as a widespread clinical tool, it is imperative to harmonize WM bundle segmentations and develop protocols aimed to be used in clinical settings. The EADC‐ADNI Harmonized Hippocampal Protocol achieved such standardization through a series of steps that must be reproduced for every WM bundle. This article is an observation of the problematic. A specific bundle segmentation protocol was used in order to provide a real‐life example, but the contribution of this article is to discuss the need for reproducibility and standardized protocol, as for any measurement tool. This study required the participation of 11 experts and 13 nonexperts in neuroanatomy and “virtual dissection” across various laboratories and hospitals. Intra‐rater agreement (Dice score) was approximately 0.77, while inter‐rater was approximately 0.65. The protocol provided to participants was not necessarily optimal, but its design mimics, in essence, what will be required in future protocols. Reporting tractometry results such as average fractional anisotropy, volume or streamline count of a particular bundle without a sufficient reproducibility score could make the analysis and interpretations more difficult. Coordinated efforts by the diffusion MRI tractography community are needed to quantify and account for reproducibility of WM bundle extraction protocols in this era of open and collaborative science.  相似文献   
99.
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号